JPH08507519A - 結晶性セフチオフル遊離酸 - Google Patents
結晶性セフチオフル遊離酸Info
- Publication number
- JPH08507519A JPH08507519A JP6520025A JP52002594A JPH08507519A JP H08507519 A JPH08507519 A JP H08507519A JP 6520025 A JP6520025 A JP 6520025A JP 52002594 A JP52002594 A JP 52002594A JP H08507519 A JPH08507519 A JP H08507519A
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- ceftiofur
- formula
- compound
- free acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.7-[2-(2-アミノ-1,3-チアゾール-4-イル)-2-メトキシイミノ)ア セトアミド]-3-[(フル-2-イルカルボニル)チオメチル]-3-セフェム-4- カルボン酸である式I: で示される結晶性化合物。 2.以下のx-線粉末回折特性: 3.式I: で示される化合物よりなる組成物において、 式Iの該化合物の少なくとも40%が結晶性である改良。 4.さらに、医薬上許容される担体または賦形剤よりなる請求項3記載の組成物 。 5.該改良が、式Iの化合物が少なくとも50%の結晶性であることによって特 徴付けられる請求項3記載の組成物。 6.該改良が、式Iの化合物が少なくとも70%の結晶性であることによって特 徴付けられる請求項5記載の化合物。 7.式I: で示される結晶性化合物よりなる医薬組成物。 8.さらに、医薬上許容される担体または賦形剤よりなる請求項7記載の組成物 。 9.徐放性である請求項7記載の組成物。 10.さらに、約20ないし200mg/mlの式Iの化合物よりなる請求項7 記載の組成物。 11.皮下または筋肉内注射によって投与される請求項7記載の組成物。 12.非水性である請求項7記載の組成物。 13.該非水性組成物が油性物である請求項12記載の組成物。 14.該油性物が:トウモロコシ油、落花生油、ゴマ油、オリーブ油、パーム油 、サフラワー油、ダイズ油、綿実油、菜種油、ヒマワリ油およびそれらの混合物 よりなる群から選択される請求項13記載の組成物。 15. a)水混和性溶媒中の式I: の化合物の溶液を、20℃および60℃の間の温度の水と合わせる工程よりなる 式I: の結晶性遊離酸の製法。 16.該溶媒が、アセトン、テトラヒドロフラン(THF)およびエタノールよ りなる群から選択される請求項15記載の製法。 17.該溶媒がテトラヒドロフラン(THF)である請求項16記載の製法。 18.該水が40℃および60℃の間の温度である請求項15記載の製法。 19.該水が約50℃である請求項18記載の製法。 20.水の式Iの化合物のTHF溶液に対する比が10:1ないし2:1の範囲 である請求項17記載の製法。 21.水の式Iの化合物のTHF溶液に対する比が約3:1である請求項20記 載の製法。 22.さらに: b)工程a)から得られた混合物を30分間および24時間の間の時間攪拌す ることからなる請求項15記載の製法。 23.該時間が30分間および4時間の間である請求項22記載の製法。 24.該時間が30分間および1時間の間である請求項23記載の製法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3329193A | 1993-03-12 | 1993-03-12 | |
US08/033,291 | 1993-03-12 | ||
PCT/US1994/001862 WO1994020505A1 (en) | 1993-03-12 | 1994-03-07 | Crystalline ceftiofur free acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08507519A true JPH08507519A (ja) | 1996-08-13 |
JP3852946B2 JP3852946B2 (ja) | 2006-12-06 |
Family
ID=21869579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52002594A Expired - Lifetime JP3852946B2 (ja) | 1993-03-12 | 1994-03-07 | 結晶性セフチオフル遊離酸 |
Country Status (31)
Country | Link |
---|---|
US (1) | US5721359A (ja) |
EP (1) | EP0690864B1 (ja) |
JP (1) | JP3852946B2 (ja) |
KR (1) | KR100296810B1 (ja) |
CN (1) | CN1055090C (ja) |
AT (1) | ATE202109T1 (ja) |
AU (1) | AU694419B2 (ja) |
BR (1) | BR1101034A (ja) |
CA (1) | CA2155322C (ja) |
CZ (1) | CZ289332B6 (ja) |
DE (2) | DE122005000055I2 (ja) |
DK (1) | DK0690864T3 (ja) |
ES (1) | ES2157254T3 (ja) |
FI (1) | FI120307B (ja) |
FR (1) | FR05C0045I2 (ja) |
GR (1) | GR3036514T3 (ja) |
HU (1) | HU222244B1 (ja) |
IL (1) | IL108910A (ja) |
LU (1) | LU91206I2 (ja) |
LV (1) | LV12889B (ja) |
NL (1) | NL300208I2 (ja) |
NO (2) | NO313199B1 (ja) |
NZ (1) | NZ263002A (ja) |
PL (1) | PL184611B1 (ja) |
PT (1) | PT690864E (ja) |
RU (1) | RU2136685C1 (ja) |
SI (1) | SI0690864T1 (ja) |
SK (1) | SK283674B6 (ja) |
TW (1) | TW267170B (ja) |
WO (1) | WO1994020505A1 (ja) |
ZA (1) | ZA941586B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006514629A (ja) * | 2002-11-19 | 2006-05-11 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 修飾されたビヒクルを含む医薬組成物 |
JP2012509337A (ja) * | 2008-11-19 | 2012-04-19 | メリアル リミテッド | セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤 |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736151A (en) * | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
US6074657A (en) * | 1997-03-20 | 2000-06-13 | Pharmacia & Upjohn Company | Administration of an injectable antibiotic in the ear of an animal |
US7829100B2 (en) * | 2000-09-12 | 2010-11-09 | Teagarden Dirk L | Pharmaceutical composition having modified carrier |
NZ524694A (en) * | 2000-09-12 | 2005-05-27 | Upjohn Co | Pharmaceutical composition having modified carrier |
KR100423895B1 (ko) * | 2001-02-19 | 2004-03-24 | 주식회사 엘지생명과학 | 셉티오퍼 하이드로클로라이드의 현탁제 조성물 |
MXPA04000294A (es) * | 2001-07-10 | 2004-05-04 | Pharmacia & Upjhon Company | Tiacin oxazolidinonas cristalinas. |
CA2455050C (en) | 2001-08-15 | 2007-02-20 | Pharmacia & Upjohn Company | Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
US20030181398A1 (en) † | 2002-03-21 | 2003-09-25 | Brown Scott A. | Method of administering an injectable antibiotic to an animal |
US20040022815A1 (en) * | 2002-08-05 | 2004-02-05 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
KR20040015622A (ko) * | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물 |
US20040115822A1 (en) * | 2002-09-12 | 2004-06-17 | Schapaugh Randal Lee | Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
US20040115837A1 (en) * | 2002-11-27 | 2004-06-17 | Schapaugh Randal Lee | Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
ES2329244T3 (es) * | 2003-03-27 | 2009-11-24 | Basilea Pharmaceutica Ag | Cefalosporina en forma cristalina. |
US8039482B2 (en) | 2004-03-25 | 2011-10-18 | Astellas Pharma Inc. | Composition of solifenacin or salt thereof for use in solid formulation |
US7815939B2 (en) | 2005-07-20 | 2010-10-19 | Astellas Pharma Inc. | Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms |
BRPI0617561A2 (pt) * | 2005-10-12 | 2011-08-23 | Orchid Chemicals & Pharm Ltd | sal de sódio cristalino antibiótico de cefalosporina |
US8470809B2 (en) * | 2005-10-12 | 2013-06-25 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
CN101835750B (zh) | 2007-08-22 | 2013-07-17 | 阿斯利康(瑞典)有限公司 | 环丙基酰胺衍生物 |
EP2303026B1 (en) | 2008-06-17 | 2020-09-09 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
WO2010020871A2 (en) * | 2008-08-22 | 2010-02-25 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
SG172926A1 (en) * | 2009-01-30 | 2011-08-29 | Glaxosmithkline Llc | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
BR112012020780A2 (pt) * | 2010-02-18 | 2016-05-03 | Astrazeneca Ab | forma sólida, composição farmacêutica, e, uso de uma forma sólida. |
BR112012020629A2 (pt) | 2010-02-18 | 2018-06-19 | Astrazeneca Ab | forma cristalina, e, método para a terapia de um distúrbio |
CA2834999A1 (en) * | 2011-05-02 | 2012-11-08 | Zoetis Llc | Novel cephalosporins useful as antibacterial agents |
CN104039369B (zh) | 2011-07-20 | 2017-06-16 | 布莱阿姆青年大学 | 疏水性塞拉集宁化合物和包含该化合物的装置 |
EP2760454B1 (en) | 2011-09-13 | 2018-08-29 | Brigham Young University | Products for healing of tissue wounds |
US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
CN104080459B (zh) | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | 用于治疗骨疾病和断骨的组合物 |
CA2859325A1 (en) | 2011-12-21 | 2013-07-25 | Brigham Young University | Oral care compositions |
CN102584855B (zh) * | 2012-02-16 | 2014-06-25 | 青岛科技大学 | 一种改进的头孢噻呋的制备方法 |
US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
US10039285B2 (en) | 2012-05-02 | 2018-08-07 | Brigham Young University | Ceragenin particulate materials and methods for making same |
BR112015008804A2 (pt) | 2012-10-17 | 2017-07-04 | Univ Brigham Young | tratamento e prevenção de mastite |
WO2014087972A1 (ja) * | 2012-12-03 | 2014-06-12 | 株式会社カネカ | 還元型補酵素q10誘導体およびその製造方法 |
WO2014107740A2 (en) | 2013-01-07 | 2014-07-10 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
BR112015023747B1 (pt) | 2013-03-15 | 2023-04-18 | Brigham Young University | Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença |
US11524015B2 (en) | 2013-03-15 | 2022-12-13 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
RU2546675C2 (ru) * | 2013-04-11 | 2015-04-10 | Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП") | Способ определения степени кристалличности составов на основе дифениламина |
US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
EP3042893B1 (en) * | 2013-09-05 | 2018-10-31 | Mitsubishi Tanabe Pharma Corporation | Novel crystalline arylalkylamine compound and method for producing same |
US11690855B2 (en) | 2013-10-17 | 2023-07-04 | Brigham Young University | Methods for treating lung infections and inflammation |
US20150203527A1 (en) | 2014-01-23 | 2015-07-23 | Brigham Young University | Cationic steroidal antimicrobials |
CA2844321C (en) | 2014-02-27 | 2021-03-16 | Brigham Young University | Cationic steroidal antimicrobial compounds |
US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
MX2017005120A (es) * | 2014-10-21 | 2018-02-12 | Ariad Pharma Inc | Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil) fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] pirimidin-2,4-diamina. |
US10370403B2 (en) | 2015-04-22 | 2019-08-06 | Brigham Young University | Methods for the synthesis of ceragenins |
US9527883B2 (en) | 2015-04-22 | 2016-12-27 | Brigham Young University | Methods for the synthesis of ceragenins |
KR101753842B1 (ko) * | 2015-05-12 | 2017-07-04 | 한국화학연구원 | 불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법 |
US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
CN106543203B (zh) * | 2015-09-18 | 2019-07-02 | 瑞普(天津)生物药业有限公司 | 一种长效头孢噻呋自由酸晶体的制备方法 |
CA3011323A1 (en) * | 2016-01-22 | 2017-07-27 | Sandoz Ag | Crystalline eravacycline bis-hydrochloride |
US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
KR101898282B1 (ko) * | 2016-05-24 | 2018-09-13 | 주식회사 고려비엔피 | 항생제의 서방형 수의학적 조성물 및 이의 제조방법 |
EP3481820B1 (en) | 2016-07-07 | 2023-10-18 | Cyclerion Therapeutics, Inc. | Solid forms of an sgc stimulator |
US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
US11186556B1 (en) * | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
TW202233625A (zh) * | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Fgfr抑制劑及其製造及使用方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1207933B (de) * | 1962-12-26 | 1965-12-30 | American Home Prod | Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin |
US3489752A (en) * | 1967-09-05 | 1970-01-13 | Bristol Myers Co | 7-amino-cephalosporanic and decephalosporanic acid derivatives |
DK154939C (da) * | 1974-12-19 | 1989-06-12 | Takeda Chemical Industries Ltd | Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf |
DE2760123C2 (de) * | 1976-01-23 | 1986-04-30 | Roussel-Uclaf, Paris | 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
GB1532682A (en) * | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
FR2479229B1 (fr) * | 1980-03-26 | 1986-01-17 | Clin Midy | Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives |
IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
US4400503A (en) * | 1981-10-30 | 1983-08-23 | Eli Lilly And Company | Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid |
DE3313818A1 (de) * | 1983-04-16 | 1984-10-18 | Hoechst Ag, 6230 Frankfurt | Neue kristallmodifikation von ceftazidim |
KR890002631B1 (ko) * | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
IT1181672B (it) * | 1984-10-25 | 1987-09-30 | Upjohn Co | Cefalosporina alogenidrato cristallino |
US4902683A (en) * | 1984-10-25 | 1990-02-20 | The Upjohn Company | Crystalline cephalosporin hydrohalide salts |
US4937330A (en) * | 1985-08-12 | 1990-06-26 | The Upjohn Company | Conversion of cephalosporin hydrohalide salt to alkali metal salt |
GB8608962D0 (en) * | 1986-04-12 | 1986-05-14 | Beecham Group Plc | Beta-lactam antibiotics |
IT1214587B (it) * | 1986-12-23 | 1990-01-18 | Giovanni Bonfanti | Metodo per la produzione diprodotti cristallini puri. |
ATE76874T1 (de) * | 1987-02-02 | 1992-06-15 | Lilly Co Eli | Verfahren zur herstellung von ceftazidimepentahydrat. |
DE3869135D1 (de) * | 1987-07-29 | 1992-04-16 | Upjohn Co | Kontrollierte freisetzung von antibiotika-salzen aus einem implantat. |
AU617377B2 (en) * | 1987-11-10 | 1991-11-28 | Pharmacia & Upjohn Company | Cephalosporin antibiotics |
US4877782A (en) * | 1988-02-16 | 1989-10-31 | The Upjohn Company | Zinc ceftiofur complexes |
-
1994
- 1994-03-07 CN CN94191448A patent/CN1055090C/zh not_active Expired - Lifetime
- 1994-03-07 EP EP94910721A patent/EP0690864B1/en not_active Expired - Lifetime
- 1994-03-07 NZ NZ263002A patent/NZ263002A/en not_active IP Right Cessation
- 1994-03-07 JP JP52002594A patent/JP3852946B2/ja not_active Expired - Lifetime
- 1994-03-07 ZA ZA941586A patent/ZA941586B/xx unknown
- 1994-03-07 PT PT94910721T patent/PT690864E/pt unknown
- 1994-03-07 DE DE122005000055C patent/DE122005000055I2/de active Active
- 1994-03-07 DK DK94910721T patent/DK0690864T3/da active
- 1994-03-07 RU RU95121942A patent/RU2136685C1/ru active
- 1994-03-07 HU HU9501960A patent/HU222244B1/hu active Protection Beyond IP Right Term
- 1994-03-07 SK SK1114-95A patent/SK283674B6/sk not_active IP Right Cessation
- 1994-03-07 KR KR1019950703858A patent/KR100296810B1/ko not_active IP Right Cessation
- 1994-03-07 DE DE69427469T patent/DE69427469T2/de not_active Expired - Lifetime
- 1994-03-07 SI SI9430374T patent/SI0690864T1/xx unknown
- 1994-03-07 ES ES94910721T patent/ES2157254T3/es not_active Expired - Lifetime
- 1994-03-07 PL PL94310556A patent/PL184611B1/pl unknown
- 1994-03-07 AU AU63510/94A patent/AU694419B2/en not_active Expired
- 1994-03-07 US US08/549,821 patent/US5721359A/en not_active Expired - Lifetime
- 1994-03-07 CA CA002155322A patent/CA2155322C/en not_active Expired - Lifetime
- 1994-03-07 WO PCT/US1994/001862 patent/WO1994020505A1/en active IP Right Grant
- 1994-03-07 AT AT94910721T patent/ATE202109T1/de active
- 1994-03-07 CZ CZ19952290A patent/CZ289332B6/cs unknown
- 1994-03-09 IL IL10891094A patent/IL108910A/en not_active IP Right Cessation
- 1994-03-12 TW TW083102155A patent/TW267170B/zh not_active IP Right Cessation
-
1995
- 1995-09-11 FI FI954250A patent/FI120307B/fi not_active IP Right Cessation
- 1995-09-11 NO NO19953564A patent/NO313199B1/no not_active IP Right Cessation
-
1997
- 1997-05-14 BR BR1101034-7A patent/BR1101034A/pt active IP Right Grant
-
2001
- 2001-09-04 GR GR20010401374T patent/GR3036514T3/el unknown
-
2002
- 2002-06-13 LV LVP-02-107A patent/LV12889B/lv unknown
-
2005
- 2005-11-16 LU LU91206C patent/LU91206I2/fr unknown
- 2005-11-17 FR FR05C0045C patent/FR05C0045I2/fr active Active
- 2005-11-18 NO NO2005025C patent/NO2005025I2/no unknown
- 2005-11-21 NL NL300208C patent/NL300208I2/nl unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006514629A (ja) * | 2002-11-19 | 2006-05-11 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 修飾されたビヒクルを含む医薬組成物 |
JP4656945B2 (ja) * | 2002-11-19 | 2011-03-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 修飾されたビヒクルを含む医薬組成物 |
JP2012509337A (ja) * | 2008-11-19 | 2012-04-19 | メリアル リミテッド | セフチオフルおよびケトプロフェンとまたはセフチオフルとベンジルアルコールとを含む製剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08507519A (ja) | 結晶性セフチオフル遊離酸 | |
KR0180798B1 (ko) | 결정성 페니실린 유도체, 그의 제법 및 용도 | |
US6486149B2 (en) | Composition comprising a crystallographically stable, amorphous cephalosporin and processes for the preparation thereof | |
JP3403206B2 (ja) | セフジトレン ピボキシル結晶性物質及びその製造法 | |
JPS62174018A (ja) | 細菌性感染症治療剤 | |
JPS6145626B2 (ja) | ||
EP1389462A1 (en) | Amorphous cefditoren pivoxil composition and process for producing the same | |
JPS6119605B2 (ja) | ||
JP2703964B2 (ja) | セファロスポリン抗生物質類 | |
US3822256A (en) | Crystalline monohydrates of sodium and potassium cephalexin | |
CS195746B2 (en) | Process for preparing crystalline methanolate of natrium salt of cephamandole | |
JPH01199977A (ja) | セファロスポリン誘導体の結晶、その製造法およびそれらを有効成分とする医薬組成物 | |
JPS6052716B2 (ja) | 抗生物質 | |
JPH11512730A (ja) | ペニシリングリコレート |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051026 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060627 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060815 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060905 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090915 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100915 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110915 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110915 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120915 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120915 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130915 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |